Business in the Burbs

EpiCept gets marketing rights in Europe

October

EpiCept. Corp. of Eastview said regulators in Europe have approved the companyâ€™s application to market Ceplene, a drug for adults with acute myeloid leukemia. The approval allows the company to market the drug in 27 European Union states, as well as Iceland, Liechtenstein and Norway. The company also wants to get permission to market the drug in North America.

This entry was posted on Thursday, October 9th, 2008 at 8:59 am by Allan Drury. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.